Company news
Insilico Medicine Cayman Topco (HKEX:3696) news
Insilico Medicine Cayman Topco news releases on 6ix. Latest, Sep 30, 2026: VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL MOLECULE…
Press releases & updates
VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL MOLECULE GIPR ANTAGONIST FOR POTENTIAL INTERVENTION OF OBESITY AND RELATED DISORDERS
September 30, 2026
Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study
September 17, 2026
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
September 8, 2026
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
September 1, 2026
Commercialization Roadmap Validated with Three-digit Million-dollar Revenue, Insilico Medicine Announces Interim Results for the First Half of 2026
August 27, 2026
Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
August 26, 2026
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths
August 17, 2026
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
August 14, 2026
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
August 12, 2026
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
August 11, 2026
AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
August 4, 2026
Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
July 30, 2026
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
July 29, 2026
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
July 27, 2026
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
July 22, 2026
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
July 7, 2026
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
July 7, 2026
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
June 22, 2026
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
June 17, 2026
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
May 12, 2026
Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
April 27, 2026
Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
April 21, 2026
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
March 13, 2026
Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
March 4, 2026
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
February 10, 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
February 6, 2026
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
February 5, 2026
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
February 3, 2026
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
January 27, 2026
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
January 23, 2026
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
January 22, 2026
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
January 19, 2026
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
January 12, 2026
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
January 3, 2026
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
December 30, 2025